Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib in Relapsed or Refractory Hematologic Malignancies
NCT03162536Phase 2Active, not recruiting
- Start
- Jun 2017
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nemtabrutinib in B-cell lymphoma (BCL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL) and 6 more (10 arms). Primary endpoints: Dose Limiting Toxicity, Adverse Events and 3 more. Started Jun 2017; status: active, not recruiting.
02
Drugs
nemtabrutinib
03
Conditions
B-cell lymphoma (BCL)small lymphocytic lymphoma (SLL)chronic lymphocytic leukemia (CLL)Waldenstrom macroglobulinemia (WM)Mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03162536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162536.